MacroGenics Announces CMO Departure and Appointment
Ticker: MGNX · Form: 8-K · Filed: 2024-10-30T00:00:00.000Z
Sentiment: neutral
Topics: management-change, personnel
TL;DR
CMO out, new CMO in at MacroGenics. Big changes in medical leadership.
AI Summary
On October 25, 2024, MacroGenics, Inc. filed an 8-K report detailing several key events. The company announced the departure of Dr. Scott R. Lippman as Chief Medical Officer and Executive Vice President, effective October 25, 2024. Concurrently, Dr. Nicholas Saccomano was appointed as the new Chief Medical Officer. The filing also includes information regarding compensatory arrangements for certain officers and other events.
Why It Matters
This filing signals a leadership change in MacroGenics' medical operations, which could impact the company's drug development and clinical trial strategies.
Risk Assessment
Risk Level: medium — Leadership changes in critical roles like Chief Medical Officer can introduce uncertainty regarding strategic direction and execution.
Key Players & Entities
- MacroGenics, Inc. (company) — Registrant
- Dr. Scott R. Lippman (person) — Departing Chief Medical Officer
- Dr. Nicholas Saccomano (person) — Appointed Chief Medical Officer
- October 25, 2024 (date) — Effective date of departure and appointment
FAQ
Who has been appointed as the new Chief Medical Officer at MacroGenics?
Dr. Nicholas Saccomano has been appointed as the new Chief Medical Officer.
When was Dr. Scott R. Lippman's departure effective?
Dr. Scott R. Lippman's departure was effective October 25, 2024.
What is MacroGenics, Inc.'s principal executive office address?
MacroGenics, Inc.'s principal executive office is located at 9704 Medical Center Drive, Rockville, Maryland 20850.
What is the SIC code for MacroGenics, Inc.?
The Standard Industrial Classification (SIC) code for MacroGenics, Inc. is 2834, Pharmaceutical Preparations.
What section of the Securities Exchange Act of 1934 does this Form 8-K report pursuant to?
This Form 8-K reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 875 words · 4 min read · ~3 pages · Grade level 12.6 · Accepted 2024-10-30 07:40:01
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share MGNX Nasdaq Global Select
Filing Documents
- d891583d8k.htm (8-K) — 27KB
- d891583dex991.htm (EX-99.1) — 10KB
- 0001193125-24-247017.txt ( ) — 159KB
- mgnx-20241025.xsd (EX-101.SCH) — 3KB
- mgnx-20241025_lab.xml (EX-101.LAB) — 17KB
- mgnx-20241025_pre.xml (EX-101.PRE) — 11KB
- d891583d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit Number Description of Exhibit 99.1 Press Release dated October 30, 2024. 104 Cover Page Interactive Data File (formatted as Inline XBRL). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 30, 2024 MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel